SAFETY OF ABIRATERONE ACETATE (AA) IN PATIENTS WITH CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND CONCOMITANT CARDIAC RISK

被引：0
|
作者：
Procopio, G. [1 ]
Verzoni, E. [1 ]
Testa, I. [1 ]
Stagni, S. [2 ]
Villa, S. [2 ]
Valdagni, R. [2 ]
De Braud, F. G. M. [1 ]
机构：
[1] Ist Nazl Tumori Milano, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：305 / 305
页数：1
相关论文
共 50 条
  • [1] Safety of abiraterone acetate (AA) in castration-resistant prostate cancer (CRPC) patients with concomitant cardiovascular disease.
    Procopio, Giuseppe
    Verzoni, Elena
    Testa, Isabella
    Biasoni, Davide
    Torelli, Tullio
    Nicolai, Nicola
    Salvioni, Roberto
    Valdagni, Riccardo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [2] Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors
    Procopio, Giuseppe
    Grassi, Paolo
    Testa, Isabella
    Verzoni, Elena
    Torri, Valter
    Salvioni, Roberto
    Valdagni, Riccardo
    de Braud, Filippo
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (05): : 479 - 482
  • [3] Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC)
    Bianchini, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] A phase II trial of abiraterone acetate (AA) without prednisone in castration resistant prostate cancer (CRPC).
    Mckay, Rana R.
    Werner, Lillian
    Jones, Alexandra
    Choudhury, Atish Dipankar
    Pomerantz, Mark
    Sweeney, Christopher
    Bubley, Glenn J.
    Slovin, Susan F.
    Morris, Michael J.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] The impact of statin use on abiraterone acetate (AA) treatment duration in patients with castration-resistant prostate cancer (CRPC).
    Harshman, Lauren Christine
    Werner, Lillian
    Nakabayashi, Mari
    Tripathi, Abhishek
    Mckay, Rana R.
    Wang, Xiaodong
    Pomerantz, Mark
    Mucci, Lorelei A.
    Taplin, Mary-Ellen
    Sweeney, Christopher
    Lee, Gwo-Shu Mary
    Kantoff, Philip W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [6] Clinical benefit on abiraterone acetate (AA) in patients (pts) with PTEN loss castration-resistant prostate cancer (CRPC)
    Omlin, A.
    Pezaro, C.
    Reid, A.
    Rodrigues, D. Nava
    Riisnaes, R.
    Miranda, S.
    Tunariu, N.
    Lorente, D.
    Attard, G.
    De Bono, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S707 - S707
  • [7] Association of biomarkers with cardiac events during abiraterone acetate treatment in castration resistant prostate cancer (CRPC)
    Zanardi, Silvia
    Campora, Sara
    Puntoni, Matteo
    Piccininno, Marco
    Piccardo, Arnoldo
    Naserl, Mehrdad Shoushtari Zadeh
    Defferrarl, Carlotta
    Biscaldi, Ennio
    Antonucci, Giancarlo
    Ricci, Damiano
    Mori, Marco
    De Consi, Andrea
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Reid, A. H.
    Attard, G.
    Danila, D.
    Ryan, C. J.
    Thompson, E.
    Kheoh, T.
    Molina, A.
    Small, E.
    Scher, H.
    De-Bono, J. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors
    Verzoni, Elena
    Grassi, Paolo
    Ratta, Raffaele
    Niger, Monica
    De Braud, Filippo
    Valdagni, Riccardo
    Procopio, Giuseppe
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (05) : 323 - 330
  • [10] Abiraterone acetate for castration resistant prostate cancer
    Shah, Shreya
    Ryan, Charles
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (04) : 563 - 570
12345